Ann: Prima Raises $20 million in Share Purchase P, page-14

re: Ann: Prima Raises $20 million in Share Pu... A summary of CVac's long and linear progression towards FDA approval.

There is now light at the end of the tunnel.


Commencement of CVac Phase I trial - July 2001

Tumour-specific responses in CVac Phase I - May 2002

Two CVac patients have enjoyed two years of progression free survival - Jul 2003

Phase IIa trial of CVac commences - Jul 2004

Favourable Phase IIa results for CVac - Mar 2007

Change of board and management - Nov 2007

Dendreon Phase III data - Apr 2009

Springtree convertible note funding - Jul 2009

FDA clears CVAc Phase IIb trial - Aug 2009

CVac Phase IIb trial commenced - Jul 2010

Springtree facility closed out - Jan 2011

And the latest:

Dubai Hospital City Centre enters agreement to treat patients with CVac - May 2011

SPP oversubscribed and sufficient funds for Phase III testing - June 2011


And nine reasons to own Prima Biomed:


1.PRR's CVac technology performed well in Phase IIa

2. Ovarian cancer is a large market of unmet medical need.

3. CVac can be used for other cancer indications.

4. There is now a clear pathway to Phase III and regulatory approval.

5. The nearness of commercial revenues from CVac warrants a higher market cap for PRR.

6. Dendreon has helped pioneer the regulatory pathway for CVac.

7. PRR is a well-managed company.

8. There is potential for PRR to realise value from non-core assets.

9. Our new target price is 75 cents per share.

http://www.primabiomed.com.au/investor/analyst_reports_pdf/Prima20110519.pdf